Dr. Cai had four years of clinical practice in China and finished a master degree in tumor immunology at CAMS/PUMC before he moved to Boston to obtain his Ph.D. degree from 1995 and 2001 in the area of cancer biology and immunology. Over past 15 years, he accumulated experience in pre-clinical and clinical studies at DFCI/HMS. He then moved to industry since 2018 to cover oncology clinical trial operation including trial strategy and biomarker design/implementation. The disease areas he has been involved span from blood cancers to solid tumors. He is interested in multiple investigational drug modalities including small molecule drugs, immune-oncology, and adaptive cellular therapies. He pays particular attention to mechanism-based biomarker and clinical trial design. He believes that the ultimate goal of clinical trials is to match study drugs to patients with appropriate tumor profiling (either genomic or TME related) to meet unmet medical needs in the clinic.

* Dinner will be first come, first served.